Condition: Non-Small Cell Lung Cancer · Sponsor: AstraZeneca
This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of various treatment combinations. This study will be conducted in approximately 80 centers globally across 10 countries.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Santa Monica, California, United States | Recruiting |
| Research Site | Santa Rosa, California, United States | Not Yet Recruiting |
| Research Site | Atlanta, Georgia, United States | Recruiting |
| Research Site | Baltimore, Maryland, United States | Not Yet Recruiting |
| Research Site | Houston, Texas, United States | Not Yet Recruiting |
| Research Site | Fairfax, Virginia, United States | Recruiting |
| Research Site | Heidelberg, Australia | Not Yet Recruiting |
| Research Site | Nedlands, Australia | Not Yet Recruiting |
| Research Site | Woodville, Australia | Not Yet Recruiting |
| Research Site | Toronto, Ontario, Canada | Not Yet Recruiting |
| Research Site | Changsha, China | Recruiting |
| Research Site | Chengdu, China | Recruiting |
+ 71 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07098338